Cargando…
SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy
BACKGROUND: Elevated myocardial intracellular sodium ([Na(+)](i)) was shown to decrease mitochondrial calcium ([Ca(2+)](MITO)) via mitochondrial sodium/calcium exchanger (NCXMITO), resulting in decreased mitochondrial ATP synthesis. The sodium-glucose co-transporter 2 inhibitor (SGLT2i) ertugliflozi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992115/ https://www.ncbi.nlm.nih.gov/pubmed/36731341 http://dx.doi.org/10.1016/j.biopha.2023.114310 |
_version_ | 1784902269847732224 |
---|---|
author | Croteau, Dominique Baka, Tomas Young, Sara He, Huamei Chambers, Jordan M. Qin, Fuzhong Panagia, Marcello Pimentel, David R. Balschi, James A. Colucci, Wilson S. Luptak, Ivan |
author_facet | Croteau, Dominique Baka, Tomas Young, Sara He, Huamei Chambers, Jordan M. Qin, Fuzhong Panagia, Marcello Pimentel, David R. Balschi, James A. Colucci, Wilson S. Luptak, Ivan |
author_sort | Croteau, Dominique |
collection | PubMed |
description | BACKGROUND: Elevated myocardial intracellular sodium ([Na(+)](i)) was shown to decrease mitochondrial calcium ([Ca(2+)](MITO)) via mitochondrial sodium/calcium exchanger (NCXMITO), resulting in decreased mitochondrial ATP synthesis. The sodium-glucose co-transporter 2 inhibitor (SGLT2i) ertugliflozin (ERTU) improved energetic deficit and contractile dysfunction in a mouse model of high fat, high sucrose (HFHS) diet-induced diabetic cardiomyopathy (DCMP). As SGLT2is were shown to lower [Na(+)](i) in isolated cardiomyocytes, we hypothesized that energetic improvement in DCMP is at least partially mediated by a decrease in abnormally elevated myocardial [Na(+)](i). METHODS: Forty-two eight-week-old male C57BL/6J mice were fed a control or HFHS diet for six months. In the last month, a subgroup of HFHS-fed mice was treated with ERTU. At the end of the study, left ventricular contractile function and energetics were measured simultaneously in isolated beating hearts by (31)P NMR (Nuclear Magnetic Resonance) spectroscopy. A subset of untreated HFHS hearts was perfused with vehicle vs. CGP 37157, an NCX(MITO) inhibitor. Myocardial [Na(+)](i) was measured by (23)Na NMR spectroscopy. RESULTS: HFHS hearts showed diastolic dysfunction, decreased contractile reserve, and impaired energetics as reflected by decreased phosphocreatine (PCr) and PCr/ATP ratio. Myocardial [Na(+)](i) was elevated > 2-fold in HFHS (vs. control diet). ERTU reversed the impairments in HFHS hearts to levels similar to or better than control diet and decreased myocardial [Na(+)](i) to control levels. CGP 37157 normalized the PCr/ATP ratio in HFHS hearts. CONCLUSIONS: Elevated myocardial [Na(+)](i) contributes to mitochondrial and contractile dysfunction in DCMP. Targeting myocardial [Na(+)](i) and/or NCX(MITO) may be an effective strategy in DCMP and other forms of heart disease associated with elevated myocardial [Na(+)](i). |
format | Online Article Text |
id | pubmed-9992115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-99921152023-04-01 SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy Croteau, Dominique Baka, Tomas Young, Sara He, Huamei Chambers, Jordan M. Qin, Fuzhong Panagia, Marcello Pimentel, David R. Balschi, James A. Colucci, Wilson S. Luptak, Ivan Biomed Pharmacother Article BACKGROUND: Elevated myocardial intracellular sodium ([Na(+)](i)) was shown to decrease mitochondrial calcium ([Ca(2+)](MITO)) via mitochondrial sodium/calcium exchanger (NCXMITO), resulting in decreased mitochondrial ATP synthesis. The sodium-glucose co-transporter 2 inhibitor (SGLT2i) ertugliflozin (ERTU) improved energetic deficit and contractile dysfunction in a mouse model of high fat, high sucrose (HFHS) diet-induced diabetic cardiomyopathy (DCMP). As SGLT2is were shown to lower [Na(+)](i) in isolated cardiomyocytes, we hypothesized that energetic improvement in DCMP is at least partially mediated by a decrease in abnormally elevated myocardial [Na(+)](i). METHODS: Forty-two eight-week-old male C57BL/6J mice were fed a control or HFHS diet for six months. In the last month, a subgroup of HFHS-fed mice was treated with ERTU. At the end of the study, left ventricular contractile function and energetics were measured simultaneously in isolated beating hearts by (31)P NMR (Nuclear Magnetic Resonance) spectroscopy. A subset of untreated HFHS hearts was perfused with vehicle vs. CGP 37157, an NCX(MITO) inhibitor. Myocardial [Na(+)](i) was measured by (23)Na NMR spectroscopy. RESULTS: HFHS hearts showed diastolic dysfunction, decreased contractile reserve, and impaired energetics as reflected by decreased phosphocreatine (PCr) and PCr/ATP ratio. Myocardial [Na(+)](i) was elevated > 2-fold in HFHS (vs. control diet). ERTU reversed the impairments in HFHS hearts to levels similar to or better than control diet and decreased myocardial [Na(+)](i) to control levels. CGP 37157 normalized the PCr/ATP ratio in HFHS hearts. CONCLUSIONS: Elevated myocardial [Na(+)](i) contributes to mitochondrial and contractile dysfunction in DCMP. Targeting myocardial [Na(+)](i) and/or NCX(MITO) may be an effective strategy in DCMP and other forms of heart disease associated with elevated myocardial [Na(+)](i). 2023-04 2023-01-31 /pmc/articles/PMC9992115/ /pubmed/36731341 http://dx.doi.org/10.1016/j.biopha.2023.114310 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Croteau, Dominique Baka, Tomas Young, Sara He, Huamei Chambers, Jordan M. Qin, Fuzhong Panagia, Marcello Pimentel, David R. Balschi, James A. Colucci, Wilson S. Luptak, Ivan SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
title | SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
title_full | SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
title_fullStr | SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
title_full_unstemmed | SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
title_short | SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
title_sort | sglt2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992115/ https://www.ncbi.nlm.nih.gov/pubmed/36731341 http://dx.doi.org/10.1016/j.biopha.2023.114310 |
work_keys_str_mv | AT croteaudominique sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT bakatomas sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT youngsara sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT hehuamei sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT chambersjordanm sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT qinfuzhong sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT panagiamarcello sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT pimenteldavidr sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT balschijamesa sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT colucciwilsons sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy AT luptakivan sglt2inhibitorertugliflozindecreaseselevatedintracellularsodiumandimprovesenergeticsandcontractilefunctionindiabeticcardiomyopathy |